Quest Diagnostics, Inc. (DGX) Reports In-Line Q3 EPS; Lowers FY12 Outlook
Tweet
Share
E-mailGet Alerts DGX Hot Sheet
Price: $237.14 -0.94%
EPS Growth %: +10.0%
Financial Fact:
Net income attributable to Quest Diagnostics: 192M
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: +10.0%
Financial Fact:
Net income attributable to Quest Diagnostics: 192M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Quest Diagnostics, Inc. (NYSE: DGX) reported Q3 EPS of $1.18, in-line with the analyst estimate of $1.18. Revenue for the quarter came in at $1.9 billion versus the consensus estimate of $1.91 billion.
Sees FY2012 EPS of $4.45-4.55, versus prior guidance of $4.45-4.60 and the consensus of $4.57. Revenues to grow approximately 0.5%, compared to the prior outlook of between 1% and 2%.
For earnings history and earnings-related data on Quest Diagnostics, Inc. (DGX) click here.
Sees FY2012 EPS of $4.45-4.55, versus prior guidance of $4.45-4.60 and the consensus of $4.57. Revenues to grow approximately 0.5%, compared to the prior outlook of between 1% and 2%.
For earnings history and earnings-related data on Quest Diagnostics, Inc. (DGX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EU proposes to curb Airbnb and short-term rentals amid housing shortage
- JPMorgan Starts Bytes Technology Group PLC (BYIT:LN) at Underweight
- Goldman Sachs Downgrades Schindler Holding AG (SCHN:SW) (SHLAF) to Sell
Create E-mail Alert Related Categories
Earnings, Guidance, Hot GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
